CNConnect Biopharma Holdings Limited CNTB · NASDAQ
$0.91 +0.01% (+$0.00)
- Market cap
- $57.1M
- Enterprise value
- $19.4M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 891.7x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -136.2%
- Gross margin
- 100.0%
- Net margin
- -86,687.5%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- -0.22
- Free float
- 26.2%
About the company
Connect Biopharma Holdings Limited (CNTB) is an international biotechnology company focused on researching, developing, and commercializing new drugs for the treatment of immunological disorders and cancer. With a primary focus on innovative therapeutic strategies and biologic drugs, Connect Biopharma aims to address unmet needs in the treatment of immune disorders and cancer. The company is known for its research capabilities and ability to discover new therapeutic pathways, as well as for its commitment to high standards of safety and efficacy. Shares of Connect Biopharma Holdings Limited (CNTB) could be suitable for investors looking to invest in the biotechnology sector with an emphasis on innovations in the treatment of immune disorders and cancer.
Sector
Healthcare
Industry
Biotechnology
CEO
Barry D. Quart
Employees
64
Headquarters
San Diego
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number